6446 — PHARMAESSENTIA Income Statement
0.000.00%
Last trade - 00:00
- TWD231.94bn
- TWD212.93bn
- TWD5.11bn
- 33
- 2
- 100
- 39
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 306 | 557 | 657 | 2,882 | 5,106 |
Cost of Revenue | |||||
Gross Profit | 244 | 184 | 278 | 2,070 | 4,495 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,155 | 2,251 | 3,464 | 4,910 | 7,019 |
Operating Profit | -849 | -1,693 | -2,808 | -2,028 | -1,913 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -842 | -1,925 | -2,796 | -1,842 | -987 |
Provision for Income Taxes | |||||
Net Income After Taxes | -843 | -1,926 | -2,796 | -1,375 | -624 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -843 | -1,926 | -2,796 | -1,375 | -624 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -843 | -1,926 | -2,796 | -1,375 | -624 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.71 | -7.88 | -10.6 | -4.84 | -1.93 |
Dividends per Share |